STOCK TITAN
  1. Home
  2. News
  3. ACOGF

Alpha Cognition - ACOGF STOCK NEWS

Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOGF), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.

Alpha Cognition Inc. (ACOGF) delivers cutting-edge AI solutions through cognitive computing platforms designed for enterprise data challenges. This dedicated news hub provides investors and professionals with verified updates directly from corporate communications and trusted financial sources.

Access chronological press releases covering product milestones, financial disclosures, and strategic initiatives. Key updates include earnings announcements, technology partnerships, research breakthroughs, and leadership developments within the cognitive AI sector.

All content undergoes strict verification to ensure alignment with regulatory standards and factual accuracy. The centralized format enables efficient tracking of Alpha Cognition's progress in advancing neural network applications and industry-specific AI tools.

Bookmark this page for streamlined monitoring of ACOGF's evolving market position and technological innovations. Combine these official updates with Stock Titan's analytical tools for comprehensive investment research.

News

Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EDT.

Rhea-AI Summary
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) announces participation in the Emerging Growth Conference on April 3, 2024, presenting its lead asset, ALPHA-1062 for Alzheimer's disease. Investors can interact with the CEO and COO during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
conferences
-
News

Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease

Rhea-AI Summary
Alpha Cognition Inc. announces the filing of a new composition-of-matter patent for its lead asset, ALPHA-1062, aimed at treating mild-to-moderate Alzheimer's Disease. The patent, if approved, will secure protection for the oral formulation of ALPHA-1062 until 2044, enhancing the company's existing patent protection until 2042.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
none
-
News

Alpha Cognition Provides Business Update

Rhea-AI Summary
Alpha Cognition Inc. provides a business update on its ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, highlighting its commercialization strategy, and pipeline expansion. The company aims to launch ALPHA-1062 into the large U.S. Alzheimer’s market, targeting improved outcomes for patients and addressing physician dissatisfaction with current therapies. With a PDUFA date set for July 27, 2024, if approved, ALPHA-1062 could be a significant addition to Alzheimer’s treatment options, potentially transforming the company's position in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
News

Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment

Rhea-AI Summary
Alpha Cognition Inc. has completed a final closing for its private placement, issuing 16,965,762 units at a price of US$0.22 per unit for gross proceeds of US$3,732,467. The Company expects to use the net proceeds for research and development, general and administrative matters, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none
-
News

Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering

Rhea-AI Summary
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) has completed a fourth closing of its private placement, issuing 9,141,534 units at a price of US$0.22 per unit for gross proceeds of US$2,011,138. The company has received gross proceeds of US$4.7 million to date and is continuing the offering for up to an additional US$1.8 million. The net proceeds will be used for research and development, general and administrative matters, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
none
-
News

Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease

Rhea-AI Summary
Alpha Cognition Inc. (ACOG) announces FDA acceptance of New Drug Application (NDA) for ALPHA-1062, a treatment for mild-to-moderate Alzheimer’s Disease. PDUFA goal date set for July 27th, 2024. Adverse events for ALPHA-1062 were less than 2% with no observed insomnia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
102.03%
Tags
clinical trial
News

Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering

Rhea-AI Summary
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) has amended the terms of its private placement offering, raising US$2.7 million and expecting an additional US$3.8 million. Each unit now consists of one common share and one share purchase warrant. The company plans to use the net proceeds for research and development, general and administrative matters, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update

Rhea-AI Summary
Alpha Cognition Inc. (ACOG) reported financial results for the third quarter and nine months ended September 30, 2023, including the submission of the New Drug Application to the FDA for ALPHA-1062, a proprietary tablet formulation for Alzheimer's disease. The company also received an issued patent for ALPHA-1062, awarded a $750,000 R&D grant, and announced a private placement offering. Additionally, the company initiated work to out-license ALPHA-1062IN for traumatic brain injury applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.38%
Tags
none
-
News

Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering

Rhea-AI Summary
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) completes third closing of private placement, issuing 4,590,903 units at US$0.22 per unit for gross proceeds of US$1,009,999. Gross proceeds to date are US$2.7 million, with an additional offering of up to US$3.8 million. Net proceeds will be used for research and development, general and administrative matters, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11%
Tags
none
News

Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering

Rhea-AI Summary
Alpha Cognition completes second closing of private placement, raising $351,303
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.1%
Tags
none
Stock ACOGF logo
Alpha Cognition

OTC:ACOGF

ACOGF Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ACOGF Stock Data

35.66M
149.58M
Biotechnology
Healthcare
Link
Canada
Vancouver